Johns Hopkins University

Erimos Pharmaceuticals, LLC

University System of Maryland

Predicant Biosciences, Inc.

Jonathan Daniel Heller

Ru Chih C Huang

Rocio Alejandra Lopez

Qingqi Chen

Amanda Jean Morris

Chih-Chuan Chang

Jih Ru Hwu

Neil Frazer

Luc J Bousse

Mingqi Zhao

John T Stults

Melissa Rhodes

David Mold

Yu-Chuan Liang

Richard Dalby

Niharika Khanna

Richard Park

Elaine Lin

Uthara Srinivasan

Ko Yung King

Ke Yung King

Melissa Claire Rhodes

Jessica Andrea Blomberg

Amanda Beth Goodman

Jessica Andrea Loduca Blomberg

The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.

[object Object]

Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.

Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use

Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use

The present invention provides for compositions, kits and methods for treatment of intraepithelial neoplasia, where the compositions include catecholic butanes, which include NDGA derivatives.

Methods and compositions for treatment of intraepithelial neoplasia

Use of nordihydroguaiaretic derivatives to suppress CDC-2 and survivin, stimulate apoptosis, and treat tumors.

Method for treatment of tumors using nordihydroguaiaretic acid derivatives

The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such as NDGA or its derivatives are administered to one or more subjects in need of treatment by a route other than direct injection into the affected tissues or topical application on affected tissues.

Methods for delivery of catecholic butanes for treatment of tumors

Microfluidic devices provide substances to a mass spectrometer. The microfluidic devices include first and second surfaces, at least one microchannel formed by the surfaces, and an outlet at an edge of the surfaces which is recessed back from an adjacent portion of the edge. Hydrophilic surfaces and/or hydrophobic surfaces guide substances out of the outlet. A source of electrical potential can help move substances through the microchannel, separate substances and/or provide electrospray ionization.

Microfluidic devices and methods

Nordihydroguaiaretic acid derivatives and methods of use thereof for the treatment of tumors.

Nordihydroguaiartic derivatives for use in treatment of tumors

Method for regulation of gene expression in eukaryotic cells using nordihydroguaiaretic acid derivatives

Nordihydroguaiaretic derivatives for use in treatment of tumors

A method for using nordihydroguiaretic acid derivatives, in particular tetramethyl nordihydroguiaretic acid and tetraglycinal nordihydroguiaretic acid, for the localized treatment of tumors induced by human papillomavirus.

Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N

Growing community of inventors

San Francisco, CA, United States of America

Jonathan Daniel Heller